17 KB366 KB16 KB192920262005Besednjak-Kocijančič, Lilijanaštevilka:5letnik:74str. 289-291ISSN:1318-0347COBISSID:19280089URN:URN:NBN:SI:doc-M8MREVIWslSlovensko zdravniško društvoZdravniški vestnikAdministration, InhalationAsthmaAstmababyBody HeightBody WeightchildChild DevelopmentDojenčekDrug TherapyGlucocorticoids, SyntheticGlukokortikoidi umetniInfantinhalatorjiotrociOtrok, razvojrastTelesna težaTelesna višinatherapyZdravilo, inhalacijska uporabazdravljenjeVpliv daljšega zdravljenja z inhalacijskimi glukokortikoidi na rast in telesno težo otrok, starih 6 do 24 mesecev| Assessment of influence of the long-term treatment with inhaled glucocorticoidon growth and body weight in asthmatic children aged 6 to 24 month|Background. Inhaled glucocorticoids are drugs of the first choice for the asthma treatment Their growth suppressive potential is well known. It has beensuggested that it may wane off during the first year of treatment. It has been also suspected that asthmatic children might become overweight/obese after asthma therapy. The aim of this prospective study was to assess the influence of long-term treatment with fluticasone propionate (FP) on body weight and growth in asthmatic children aged 6 to 24 month. Methods. 26 pairs of children of the same age with birth weight > 3000 g took part in 12-month parallel group trial. Group A consisted of children mith mild persistent asthma treated for the first time. Inhaled FP 100 ug twice daily was used. Group B consisted of healthy children. In each group there were 17 males and 9females. Weight and height data during 6-month prior to enrolment in the trial were retrospectively collected from the notes. Length and weight of bothchildren from a pair were measured on the same day frorn day 1 every 3 month up to a year on the same measuring instrument SPSS software 10.0 was used for statistical analyses. t-tests were employed for between-group analyses. Results. Mean weight was greater for 156g in group A (t = 0.29, p = 0.77, DF:24), and the mean length increase was greater for 0.72 cm in group B (t = -1.06, p = 0.30, DF:24). The differences between group A and B were not statistically significant. A marked decrease in mean length difference from 0.26 in the first to 0. 09 cm in the last quarter of the study was observed. Conclusions. Long-term treatment with inthaled glucocorticoids (1OO ug FP twice daily) is safe in spite to their suppressive effect on growth. The growth suppressive pote ratial of inhaled glucocorticoids is decreasing duringthe treatment. There is a no sigraificant influence on body weightIzhodišča. Inhalacijski glukokortikoidi (IGK) so izbirno zdravilo za zdravljenje astme pri otroku. Znan je njihov zaviralni vpliv na rast, ki pa naj bi ob daljšem zdravljenju z nizkimi odmerki IGKpovsem izzvenel. Otroci z astmo so debelejši od sovrstnikov, kar je lahko tudi posledica zdravjenja. S prospektivno raziskavo smo želeli ovrednotiti vpliv dolgotrajnega zdravljenja s flutikazon propionatom (FP) na rast in telesno težo otrok, starih 6-24 mesecev. Metode. V raziskavo je bilo vključeuih 26 parov otrok iste starosti, ki so ob rojstvu tehtali 3000 g ali več. V skupini A so bili otroci, ki so se prvič zdravili zaradi astme. Dvakrat dnevno so vdihovali po 100,ug FP. V skupini B so bili zdravi otroci. V vsaki skupini je bilo 17 dečkov in 9 deklic. Podatki o spreminjanju telesne teže in višine v 6 mesečnem obdobju pred raziskavo smo povzeli iz zdravstvene dokumentacije. Meritve teže in višine pri obeh otrocih iz para so bile opravljene hkrati in na isti merilni napravi vsake tri mesece. Za potrditev razlik med skupinama je bil uporabljen t-parni test. Podatki so bili obdelani v programski aplikaciji SPSS 10.0. Rezultati. Povprečna telesna teža otrok z astmo je bila za 156g večja od teže zdravih (t = 0, 29; p = 0, 77, DF:24), medtem ko je bila povprečna telesna višina za 0, 72 cm nižja od telesne višine zdravih otrok (t = -1,O6; p = 0,30;DF:24). Razliki med skupinama nista statistično značilni. Opazno je bilo zmanjšanje razlike v višini s 0,26 cm v prvem četrtletju na 0, 09 cm v zadnjemčetrtletju. Zaključki. Zdravljenje otrok z nizkim odmerkom IGK (100 ug FP dvakrat dnevno) je varna kljub vplivu na rast. Zavora rasti se zmanjšuje obdaljšem zdravljenju. Zdravilo zanemarljivo vpliva na pridobivanje telesne težeTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko zdravniško društvo